Protox Therapeutics to Present at London Biotech Investment Forum
Thursday, June 15, 2006 - Vancouver, British Columbia - Protox Therapeutics Inc. (TSX-V: PRX) announced today that Dr. Fahar Merchant, Protox's President and Chief Executive Officer, will be a featured presenter at the Sachs Associates 2nd Annual London Biotech Investment Forum to be held June 22, 2006 at the London Stock Exchange.
The Sachs Associates 2nd Annual London Biotech Investment Forum provides an opportunity for the most promising emerging growth companies to interact with and present to the European investment community.
About Protox Therapeutics:
Protox Therapeutics is a product-focused development-stage company and a leader in advancing novel, targeted protein toxin therapeutics for treatment of cancer and other diseases. Through the company’s PORxin™ technology platform, therapeutic candidates are generated by engineering the naturally occurring protein, proaerolysin. These proteins become potent anti-cancer agents when activated at a tumor site by specific proteases produced by cancer cells. Once activated, the drug punches holes in the cancer cells causing the contents to leak out and ultimately, cell death. Protox is in Phase I clinical trial with the lead compound, PRX302, for the treatment of localized prostate cancer. PRX302 is also being developed for treatment of benign prostatic hyperplasia.
For more information, contact:
Elayne Wandler
Director, Investor Relations and Corporate Communications, Protox Therapeutics Inc.
Direct: 604-688-4369
Cell: 778-865-0172
Fax: 604-688-0173
ewandler@protoxtherapeutics.com
